TARS Tarsus Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TARS

Price (delayed)

$74.29

Market cap

$3.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.08

Enterprise value

$3.13B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 45

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet ...

Highlights
Tarsus Pharmaceuticals's gross profit has soared by 105% YoY and by 13% from the previous quarter
The company's revenue has surged by 105% YoY and by 13% QoQ
The company's quick ratio fell by 36% YoY and by 12% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tarsusrx.com
Peers: OLMA OMER

Key stats

What are the main financial stats of TARS

TARS stock price

How has the Tarsus Pharmaceuticals stock price performed over time
Intraday
-3.62%
1 week
-4.31%
1 month
2.19%
1 year
33.54%
YTD
-9.27%
QTD
18.03%

Financial performance

How have Tarsus Pharmaceuticals's revenue and profit performed over time
Revenue
$606.33M
Gross profit
$565.59M
Operating income
-$48.54M
Net income
-$46.48M
Gross margin
93.3%
Net margin
-7.7%
Tarsus Pharmaceuticals's gross profit has soared by 105% YoY and by 13% from the previous quarter
The company's revenue has surged by 105% YoY and by 13% QoQ
Tarsus Pharmaceuticals's operating margin has soared by 76% YoY and by 16% from the previous quarter
Tarsus Pharmaceuticals's net margin has surged by 75% YoY and by 14% QoQ

Price vs fundamentals

How does TARS's price correlate with its fundamentals

Growth

What is Tarsus Pharmaceuticals's growth rate over time

Valuation

What is Tarsus Pharmaceuticals stock price valuation
P/E
N/A
P/B
9.22
P/S
5.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.16
The company's EPS has surged by 53% YoY and by 4.4% QoQ
TARS's P/B is 108% above its 5-year quarterly average of 4.6 and 12% above its last 4 quarters average of 8.5
The company's equity rose by 4.2% YoY
The company's revenue has surged by 105% YoY and by 13% QoQ
The P/S is 65% lower than the 5-year quarterly average of 15.9 and 11% lower than the last 4 quarters average of 6.2

Efficiency

How efficient is Tarsus Pharmaceuticals business performance
The company's return on sales has surged by 82% YoY and by 23% QoQ
TARS's return on invested capital has surged by 69% year-on-year and by 8% since the previous quarter
The ROA has soared by 61% YoY and by 9% from the previous quarter
TARS's ROE has soared by 58% YoY and by 4.9% from the previous quarter

Dividends

What is TARS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TARS.

Financial health

How did Tarsus Pharmaceuticals financials performed over time
TARS's total assets is 131% greater than its total liabilities
Tarsus Pharmaceuticals's total liabilities has soared by 63% YoY and by 14% from the previous quarter
TARS's current ratio is down by 39% YoY and by 14% from the previous quarter
Tarsus Pharmaceuticals's debt is 79% lower than its equity
The debt to equity has contracted by 4.5% YoY
The company's equity rose by 4.2% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.